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Abstract
Background: Plasma levels of atrial and brain natriuretic peptides (ANP and BNP) are increased in patients with
chronic kidney disease (CKD) complicated with deteriorated kidney function, but the relationship between the
plasma level of ANP or BNP and the future development of CKD is unclear.
Methods: We measured the plasma ANP and BNP levels of 294 local residents without CKD in a Japanese
community (56.5 ± 10.4 years, mean ± S.D.), who were followed up for the development of CKD over the next
7 years.
Results: Sixty-three residents developed CKD during the follow-up period, and the baseline level of plasma ANP of
these residents was significantly higher than in those without CKD development. Kaplan-Meier analysis showed that
the residents with higher ANP than the median value developed CKD more frequently than those with lower ANP.
The association between plasma ANP level and CKD development was found to be independent of baseline
estimated glomerular filtration rate by a Cox proportional hazards model, while this association became insignificant
when adjusted by age; plasma ANP was significantly correlated with age. Compared with ANP, the relationship
between plasma BNP and CKD development was unclear in these analyses.
Conclusions: Age-related elevation of plasma ANP levels preceded the development of CKD in the general population
of Japan, raising a possibility for ANP being involved in the development of CKD.
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Background
The cardiac hormones atrial and brain natriuretic pep-
tides (ANP and BNP) are secreted from the atria or ven-
tricles in response to increased fluid volume or elevated
blood pressure [1–6]. These natriuretic peptides act on
the kidneys, blood vessels and adrenal glands, where
they exert natriuresis, vasodilatation and an inhibitory
action on aldosterone secretion, thereby forming a nega-
tive feedback loop to reduce fluid volume or blood pres-
sure [3–6]. In recent decades, a number of functional
analysis studies have been performed, revealing that
ANP and BNP have not only natriuretic or vasodilatory
effects but also direct cardiovascular protective actions,
such as the inhibition of cardiac fibrosis and the sup-
pression of vascular smooth muscle cell proliferation
[3–6]. Their protective roles on the kidneys have also
been proposed because ANP and BNP were experimen-
tally shown to inhibit the proliferation of mesangial cells
and fibrosis of the kidneys [7–10]. In heart failure pa-
tients, augmented secretions of ANP and BNP result in
elevated plasma levels of these natriuretic peptides,
which have been widely used as markers of disease se-
verity [5, 6, 11]. Similarly, the plasma levels of these two
natriuretic peptides or N-terminal fragments of their
precursor peptides were reported to be increased in pa-
tients with chronic kidney disease (CKD) complicated by
impaired renal function, suggesting the possibility that
these peptides can be prognostic markers for the pro-
gression of CKD or the deterioration of renal function
[12–17]. In these reports, substantial numbers of the
study subjects were those who had already developed
CKD with reduced renal function; meanwhile, there are
currently limited data available about the relationship
between the future development of CKD and plasma
levels of the natriuretic peptides, ANP and BNP, in those
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without CKD [18, 19]. In the present study, we exam-
ined whether the elevation of ANP or BNP levels in
plasma is seen prior to the development of CKD by fol-
lowing up local residents without CKD for 7 years.
Methods
Study subjects and protocol
Local residents of the Kiyotake area, Miyazaki, Japan,
who underwent an annual regular health check-up from
1995 to 1999, were randomly selected for this study.
Upon visiting the community center of Kiyotake Town,
the medical history of the residents was taken, and blood
pressure was measured with an oscillometric automatic
device (BP-103iII, Colin, Japan) in a sitting position by
experienced nurses. The history taken was confirmed by
physicians, who then carried out physical examination
including auscultation. Thereafter, urine was collected
and blood was drawn from an antecubital vein. Serum
lipid and glucose levels were measured using an auto-
matic analyzer (AU2700; OLYMPUS, Tokyo, Japan) with
serum creatinine levels determined by an enzymatic
method. Residents with a fasting blood glucose level of
126 mg/dL or higher were excluded from this study to
avoid analyzing cases of CKD secondary to diabetic ne-
phropathy. In addition, we also excluded those with
medical history, symptoms or signs indicative of any
heart disease, or with overt cardiovascular diseases, be-
cause plasma levels of ANP and BNP are elevated in pa-
tients with heart failure.
Residents were judged to have CKD when the esti-
mated glomerular filtration rate (eGFR) was <60 mL/
min/1.73 m2 or spot urine protein determined by dip-
stick measurement was ≥ +1 (30 mg/dl). GFRs were cal-
culated using the following formula of the Japanese
Society of Nephrology: 194 × serum creatinine-1.094 ×
age-0.287 mL/min/1.73 m2, further multiplied by 0.739
for women [20]. Of those receiving the check-up during
the recruitment period, 294 residents judged to be
without CKD (98 males and 196 females; 56.5 ±
10.4 years, mean ± S.D.) were followed up for the de-
velopment of CKD over the next 7 years at the an-
nual health check-ups.
To measure the plasma levels of ANP and BNP, blood
was collected with 1.0 mg/mL EDTA-2Na and 500 kalli-
krein inhibitory units (KIU)/mL of aprotinin. Plasma
was then obtained by centrifugation at 3000 rpm for
10 min at 4 °C and stored at −30 °C until the assay.
Plasma levels of ANP and BNP were measured using
immunoradiometric assays specific to the two peptides,
as previously reported [21, 22].
This study was approved by the Review Committee for
Cooperative and Commissioned Research and the Ethics
Committee of the University of Miyazaki Faculty of
Medicine. All subjects examined gave their informed
consent before participating in this study.
Statistical analysis
All of the data were analyzed with IBM SPSS software
version 22.0 (IBM, Armonk, NY, USA). Two groups
were compared by either the unpaired t-test or the chi-
squared test. The rates of CKD development in the local
residents with plasma ANP or BNP level higher or lower
than the median values were compared by Kaplan-Meier
analysis and log-rank test. Both univariate and multivari-
ate Cox proportional hazard models were used to iden-
tify factors significantly associated with the development
of CKD. In addition, the relationships between plasma
levels of the natriuretic peptides and the other parame-
ters were tested by simple regression analysis. All data
are expressed as the means ± S.D. and P <0.05 was con-
sidered to be significant.
Results
Table 1 shows the basal clinical parameters and plasma
levels of ANP and BNP in the residents with or without
the development of CKD. During the follow-up period
of 7 years, 30 men and 33 women developed CKD, the
diagnosis of which was made by eGFR <60 ml/min/
1.73 m2 in 12 residents, by dipstick proteinuria ≥ +1 in
31, or by both in 20. In the comparison between the res-
idents with and without the development of CKD, the
male residents were more susceptible to CKD develop-
ment than the females. The residents with CKD develop-
ment were significantly older, showing higher arterial
Table 1 Comparison of basal parameters and plasma natriuretic




Number of subjects (male %) 231 (29) 63 (52)*
Age (year) 55.1 ± 10.3 61.9 ± 8.7*
Body mass index (kg/m2) 22.8 ± 3.1 23.3 ± 3.2
Systolic arterial pressure (mmHg) 124 ± 16 136 ± 21*
Diastolic arterial pressure (mmHg) 75 ± 11 80 ± 10*
Mean arterial pressure (mmHg) 92 ± 12 99 ± 12*
Serum creatinine (mg/dL) 0.58 ± 0.12 0.65 ± 0.13*
eGFR (ml/min/1.73 m2) 93 ± 16 86 ± 20*
Total cholesterol (mg/dL) 197 ± 36 199 ± 29
Fasting blood glucose (mg/dL) 90 ± 8 92 ± 8
ANP (pg/mL) 13.7 ± 7.0 16.8 ± 10.7*
BNP (pg/mL) 16.4 ± 14.3 23.0 ± 26.3
eGFR estimated glomerular filtration rate, ANP and BNP atrial and brain
natriuretic peptides
means ± S.D.
*P < 0.01, vs. residents without CKD development
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pressure, serum creatinine levels and lower eGFR, than
those without CKD development. The plasma level of
ANP in the residents who developed CKD was signifi-
cantly higher than in those who did not, and a similar
tendency was observed for the plasma level of BNP, but
the difference was not statistically significant.
We then divided the study subjects into two groups of
higher and lower ANP or BNP by the medians (ANP,
12.6 pg/mL; BNP 13.1 pg/mL) and compared them using
Kaplan-Meier analysis and log-rank test. As shown in
Fig. 1, the group with higher ANP showed a significantly
higher rate of CKD development than the group with
lower ANP. Similarly, the rate of CKD development
in the higher-BNP group was slightly higher, but the
difference was insignificant compared with those with
lower BNP.
The data were further analyzed using univariate and
multivariate Cox proportional hazard models, where we
used gender, age, mean arterial pressure, eGFR and ANP
as explanatory covariates, because these parameters were
found to be significantly different between the residents
with and without CKD development (Table 1). In univar-
iate analysis, all the parameters listed in Table 2 were
judged to be significantly associated with CKD develop-
ment. Next, we evaluated those parameters by multivari-
ate analyses, the results of which are shown as Models 1
and 2 in Table 3. In Model 1, because eGFR was calcu-
lated by using age and serum creatinine, we excluded
age from the analysis, identifying all the parameters
shown in this model as independently significant factors
for CKD development. When we constructed Model 2
including age, both eGFR and ANP became insignificant,
and indeed, a significant correlation was noted between
plasma ANP and age (r = 0.366, P < 0.01) by simple re-
gression analysis of the study subjects. Thus age was
found to be a powerful cofounder in the relationship be-
tween ANP and CKD development. In addition, the
ANP level was weakly, but significantly correlated with
mean arterial pressure (r = 0.148, P < 0.05) and eGFR
(r = −0.130, P < 0.05).
Discussion
Both ANP and BNP are cardiac hormones having
counter-regulatory roles against increased fluid vol-
ume and elevated blood pressure [3–6]. In patients
with heart failure, plasma levels of ANP and BNP are
progressively elevated in relation to the severity of
the disease, so they have been widely used as markers
of heart failure [4, 6, 11]. Similarly, plasma levels of
the two natriuretic peptides are elevated in patients
with chronic renal failure [12, 13], and in recent
years, elevated plasma levels of either the natriuretic
peptides or the N-terminal fragments of their precur-
sors were shown to be biomarkers for patients with
CKD: the higher the plasma levels were, the faster
the deterioration of renal function [14–17]. Compared
with these reports, there have been limited data avail-
able as to the plasma levels of ANP and BNP in the
early stage of renal impairment prior to CKD develop-
ment. Fox et al. revealed that elevation of blood levels of
BNP predicted future incident of microalbuminuria by a
population-based cohort study [18]. According to Bansal
et al., higher levels of an N-terminal peptide of the BNP
precursor were associated with rapid decline of renal
Fig. 1 Kaplan-Meier analysis of CKD development in the residents with higher or lower values of ANP (a) or BNP (b). The subjects were divided
into two groups by the median value of ANP or BNP and followed up for 7 years. The differences in the rates of CKD development were
evaluated by log-rank test
Table 2 Identification of factors associated with CKD
development by univariate analysis
Factors β Risk ratio 95 % CI
Gender (M = 1; F = 2) −0.822 0.439* 0.268–0.722
Age (years) 0.067 1.069* 1.040–1.100
Mean arterial pressure (mmHg) 0.047 1.048* 1.027–1.070
eGFR (ml/min/1.73 m2) −0.029 0.972* 0.954–0.990
ANP (pg/mL) 0.030 1.030* 1.009–1.052
eGFR estimated GFR, ANP atrial natriuretic peptide
*P < 0.01
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function and incident CKD [19]. Meanwhile, there have
been few reports showing association between plasma
levels of ANP and future development of CKD. In the
present study, we revealed that age-related elevation of
the plasma level of ANP preceded the development of
CKD in local residents without overt cardiovascular dis-
eases, while such a phenomenon was unclear for BNP
compared with ANP.
First, discussion may be focused on the mechanisms
behind the elevation of plasma ANP levels in residents
who developed CKD during the follow-up period. In the
present study, the baseline levels of plasma ANP were
found to be correlated with age, mean arterial pressure
and eGFR by simple regression, among which, aging
may have a particular importance because the associ-
ation between the plasma levels of ANP and develop-
ment of CKD was dependent of age. ANP is metabolized
in two different pathways: binding to clearance receptors
(NPR-C) and breakdown by the enzyme neutral endo-
peptidase (NEP) expressed in various organs including
the kidneys [5, 6]. It was previously reported that the re-
ceptor number of NPR-C on platelets in the elderly de-
creased, resulting in reduced clearance of ANP from the
bloodstream, compared with that in younger subjects
[23]. Also, reduction of renal function with reduced ac-
tivity of peptide hydrolysis may need to be considered
because of the correlation between the plasma ANP and
eGFR levels at baseline. On the other hand, increased se-
cretion of ANP from the cardiac atria may be a factor:
elevation of blood pressure could increase the stiffness
of the left ventricle, resulting in elevated left atrial pres-
sure, which augments the secretion of ANP [5, 6]. Thus,
it seems to be necessary to take both possibilities into
account: a decrease in clearance or breakdown and an
increase in secretion, as the mechanism for an elevated
plasma ANP level prior to the development of CKD.
Next, we may need to discuss possible roles of ANP,
the plasma levels of which were elevated prior to the de-
velopment of CKD in association with aging in the
present study. Both ANP and BNP exert blood pressure-
lowering action through natriuresis, vasodilation and the
suppression of aldosterone secretion [3–6]. Experimental
studies in vitro and in vivo showed that ANP has an
inhibitory effect on the proliferation of smooth
muscle and mesangial cells, and renal fibrosis, imply-
ing a possible kidney-protective role of this bioactive
peptide [7–10]. Clinical evidence for therapeutic ap-
plication of the natriuretic peptides to CKD patients
is limited at present, while Sezai et al. showed a pos-
sible kidney-protective effect of ANP infused into pa-
tients undergoing coronary artery bypass graft surgery
[24]. According to a retrospective study by Ng et al.,
BNP was superior to nitroglycerin in preventing GFR
decline in those with heart failure [25]. In the present
study, although an elevated BNP level prior to the de-
velopment of CKD was unclear, we may be able to
raise a possibility for ANP in modulating the develop-
ment of CKD in the general population. Recently, a
large clinical trial revealed that the inhibition of natri-
uretic peptide breakdown by the neutral peptidase
(NEP) inhibitor LCZ696 with angiotensin receptor
blockade activity improved the prognosis of patients
with heart failure [26]. A hypothesis may be raised:
further enhancement of the action of ANP could also
be a strategy for those at high risk of CKD [27]; how-
ever, neither the natriuretic peptides nor NEP inhibi-
tors have been directly proven to be effective in
suppressing the development or progression of CKD
in humans.
Lastly, limitations of this study should be raised as
follows. Plasma levels of ANP or BNP are elevated in
patients with cardiac hypertrophy or reduced left ven-
tricular function [3–6]. When recruiting the study
subjects, we excluded those with cardiac diseases,
such as heart failure and ischemic heart disease,
based on the medical history and physical examin-
ation by physicians. Meanwhile, it might have been
impossible for us to exclude subclinical cardiac condi-
tions affecting the plasma levels of ANP or BNP, be-
cause no data were available about echocardiography
or chest X-ray. Next, diagnosis of CKD was made
based on eGFR values and proteinuria determined by
Table 3 Identification of factors associated with CKD development by multivariate analyses
Model 1 Model 2
Factors β Risk ratio 95 % CI β Risk ratio 95 % CI
Gender (M = 1; F = 2) −0.698 0.498** 0.299–0.827 −0.679 0.507** 0.305–0.843
Age (years) 0.042 1.042* 1.009–1.077
Mean arterial pressure (mmHg) 0.038 1.039** 1.017–1.062 0.031 1.032** 1.009–1.055
eGFR (ml/min/1.73 m2) −0.021 0.976* 0.961–0.998 −0.013 0.987 0.968–1.006
ANP (pg/mL) 0.026 1.026* 1.002–1.052 0.013 1.013 0.986–1.040
eGFR estimated GFR, ANP atrial natriuretic peptide
*P < 0.05
**P < 0.01
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dipstick method, which is not as accurate as quantita-
tive measurement of urinary protein or albumin to
creatinine ratio. The third point is the small number
of study subjects or those developing CKD, limiting
the ability to generalize the present results. Indeed,
BNP was not found to be significantly associated with
CKD development in this study, but we are unable to
exclude possibility of this relationship because of a
lack of statistical power. Fourthly, the present data
were collected from a Japanese community and evalu-
ated by the eGFR formula for Japanese people. There-
fore, it remained to be clarified whether the present
results can be applied to other ethnic groups or
races.
Conclusions
Increased levels of plasma ANP, which were associ-
ated with aging, preceded the development of CKD in
local residents without overt cardiovascular diseases,
suggesting a possible role of this bioactive peptide in
the development of CKD in the general population of
Japan.
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